Quercetin in COVID19
Phase 3
- Conditions
- COVID19.Corona virus infection, unspecifiedU07.1
- Registration Number
- IRCT20200419047128N2
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Polymerase chain reaction (PCR) confirmed infection with COVID19
Lung involvement confirmed with chest imaging Hospitalized with: Fever (axillar or oral temperature = 38.0 °centigrade(C) or =38.6°centigrade tympanic or rectal) Or Cough
Willingness of study participant to accept randomization to any assigned treatment arm
Acceptance of non-participation in another study before the 28th day of the study
Exclusion Criteria
Autoimmune diseases (lupus, MS, etc.)
Hepatic failure Hepatit B, C,
pregnant and lactating women Not consent to participate in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Viral diagnostic test. Timepoint: The first day of the study and the end of the study (14th). Method of measurement: Polymerase chain reaction.
- Secondary Outcome Measures
Name Time Method Blood oxygen saturation percentage. Timepoint: Before and-4-7 days after starting treatment. Method of measurement: Pulse oximeter.;Cough rate. Timepoint: Before and 7 days after starting treatment. Method of measurement: Physical examination.;C-Reactive Protein (CRP). Timepoint: Before and 7 days after starting treatment. Method of measurement: ?ELISA (enzyme-linked immunosorbent assay).;IL1. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;IL6. Timepoint: Before and 7 days after starting treatment. Method of measurement: ELISA (enzyme-linked immunosorbent assay).;CBC. Timepoint: Before and 7 days after starting treatment. Method of measurement: Cell Counter.